TORONTO and HOUSTON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that on October 25, 2022, it received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company is not in compliance with the minimum bid price requirement ("Minimum Bid Requirement") of US$1.00 per share under the Nasdaq Listing Rule 5450(a)(1) based upon the closing bid price of the Company’s common stock for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq, and the Company’s operations are not affected by the receipt of the Notice.

Read more:
Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022:

See the original post:
Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®

Since launch the new product has had approximately 117% ROI

See the article here:
SciSparc: Wellution™ Successfully Launched a New Keto Gummies Apple Cider Vinegar Product and Generated $100,000 In Revenues Within 30 Days

ISELIN, N.J., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a Biologics License Application (BLA) for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD). The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023. ONS-5010, if approved, is expected to receive 12 years of regulatory exclusivity in the United States.

Original post:
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

New Orleans, Louisiana, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Software Effective Solutions Corporation (OTC: SFWJ) (“The Company”, “SFWJ”) subsidiary Medcana is pleased to announce the successful launch of test greenhouses for microclimates and genetics with five partner firms in Colombia, South America. With significantly better economics than the US and Canada, a central location for exportation to major markets, and prime cultivation characteristics, Colombia is believed by many to have significant cultivation advantages over other regions around the world.

Continue reading here:
Correction: Software Effective Solutions Subsidiary MEDCANA (OTC: SFWJ) Announces Successful Launch of Test Greenhouses for Microclimates and Genetics...

Media Release

The rest is here:
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell...

ESTERO, Fla., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Marijuana Strategic Ventures, Inc. (the “Company”)(OTC: MSVI) now Mushrooms Inc., Announces Positioning for Global Acquisitions and Shareholder Update.

Continue reading here:
Marijuana Strategic Ventures, Inc. (OTC: MSVI) Now Mushrooms Inc., Announces Positioning for Global Acquisitions and Shareholder Update

28.10.2022 at 18:30

View post:
Orion Corporation: Acquisition of Own Shares 28.10.2022

Negma Group has converted 580 convertible bonds in Oxurion resulting in a EUR 1,450,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.

Read more here:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA

NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the outcome of the meeting of the U.S. Food and Drug Administration (“FDA”) Oncologic Drugs Advisory Committee (“ODAC”), which reviewed investigational 131I-omburtamab (“omburtamab”) for the treatment of CNS/leptomeningeal metastasis from neuroblastoma. The committee voted 16 to 0 that the Company had not provided sufficient evidence to conclude that omburtamab improves overall survival.

Continue reading here:
Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab